Table 1 Patient characteristics.

From: Prognostic relevance of TROP2 expression in patients with non-small cell lung cancer receiving immunotherapy

Baseline characteristics (n = 110)

Age

 < 75/ ≥ 75 years

72 (65.5%)/38 (34.6%)

ECOG performance status

 0/1/2/3

37 (33.6%)/50 (45.5%)/16 (14.5%)/7 (6.4%)

Sex

 Male/Female

89 (80.9%)/21 (19.1%)

Smoking index

 Yes/No

92 (83.6%)/18 (16.4%)

Staging status

 III/IV/Rec. after surgery/Rec. after RT

6 (5.4%)/68 (61.8%)/24 (21.8%)/12 (10.8%)

Histology

 AD/SCC/Others

56 (50.9%)/41 (37.3%)/13 (11.8%)

PD-L1 (TPS) (%)

 ≥ 50/1–49%/ < 1%/Unknown

10 (9.1%)/51 (46.4%)/47 (42.7%)/2 (1.8%)

Any grade irAEs

 Present/Absent

77 (70.0%)/33 (30.0%)

Response by RECIST

 CR/PR/SD/PD/NE

1 (0.9%)/40 (36.4%)/33 (30.0%)/28 (25.4%)/8 (7.3%)

  1. Abbreviations: ECOG, eastern cooperative oncology group; Rec. recurrence; RT, radiation; AD, adenocarcinoma; SCC, squamous cell carcinoma; PD-L1, programmed death ligand-1; TPS, tumor proportional score; irAEs, immune-related adverse events; RECIST, response evaluation criteria in solid tumors; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; NE, not evaluable.
Back to article page